bluebird bio Ready to Rally on Regeneron Investment

BLUE and REGN are partnering on new cell therapies for cancer

Aug 6, 2018 at 9:16 AM
facebook twitter linkedin

Massachusetts-based biotech company bluebird bio (NASDAQ:BLUE) today announced a collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN) to jointly develop new cell therapies for cancer. Under the terms of the partnership, Regeneron will invest $100 million in bluebird, or $238.10 per share -- 58.7% north of BLUE's Friday close at $150.

It hasn't been the best year for BLUE shares in 2018, as they've dropped 35.6% from their March 12 closing high of $233.05, and they enter today's trading down by nearly 16% year-to-date. In fact, BLUE's 14-day Relative Strength Index (RSI) was resting at a near-oversold 34 by the end of last week.

That said, the stock is up 4.7% ahead of the bell, bouncing from a recent pullback to its 320-day moving average. And on a year-over-year basis, the equity has advanced 60%.

But given the stock's more recent technical troubles, it's no surprise to find that options players are favoring puts over calls. Schaeffer's put/call open interest ratio (SOIR) of 1.00 registers in the 91st percentile of its annual range, as speculative players have rarely been more put-skewed in the past year. And the front-month gamma-weighted SOIR, which narrows the focus to near-the-money strikes in the August series, checks in at a top-heavy 2.25.

BLUE remains heavily shorted, as well, with short interest accounting for 7.8% of the stock's float. That supply of bearish bets represents 4.9 times the equity's average daily trading volume, and a capitulation by some of the weaker shorts in light of today's news could help fuel upside for the stock.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report


Special Offers from Schaeffer's Trading Partners